Literature DB >> 26392464

Granzyme B-Mediated Activation-Induced Death of CD4+ T Cells Inhibits Murine Acute Graft-versus-Host Disease.

Wei Du1, Nicholas D Leigh1, Guanglin Bian1, Rachel E O'Neill1, Lin Mei2, Jingxin Qiu3, George L Chen4, Theresa Hahn4, Hong Liu4, Philip L McCarthy4, Xuefang Cao5.   

Abstract

Granzyme B (GzmB) has previously been shown to be critical for CD8(+) T cell-mediated graft-versus-host disease (GVHD) but dispensable for GVHD mediated by CD4(+) T cells. However, previous studies used high doses of CD4(+) T cells in MHC-mismatched models that caused rapid and lethal GVHD. Because of the hyperacute lethality, it is possible that the role of GzmB was concealed by the system. Therefore, in this study, we have titrated down the T cell dose to precisely determine the contribution of GzmB in GVHD mediated by CD4(+)CD25(-) T cells. Surprisingly, we have found that GzmB(-/-)CD4(+)CD25(-) T cells cause more severe GVHD compared with wild-type CD4(+)CD25(-) T cells in both MHC-matched and mismatched models. Mechanistic analyses reveal that although GzmB does not affect donor T cell engraftment, proliferation or tissue-specific migration, GzmB(-/-) CD4(+)CD25(-) T cells exhibit significantly enhanced expansion because of GzmB-mediated activation-induced cell death of wild-type CD4(+)CD25(-) T cells. As a result of enhanced expansion, GzmB(-/-) T cells produced higher amounts of proinflammatory cytokines (e.g., TNF-α and IFN-γ) that may contribute to the exacerbated GVHD. These results reveal that GzmB diminishes the ability of CD4(+) T cells to cause acute GVHD, which contradicts its established role in CD8(+) T cells. The differential roles suggest that targeting GzmB in selected T cell subsets may provide a strategy to control GVHD.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26392464      PMCID: PMC4610854          DOI: 10.4049/jimmunol.1500668

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation.

Authors:  T A Graubert; J F DiPersio; J H Russell; T J Ley
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

Review 2.  Hematopoietic stem-cell transplantation.

Authors:  Edward A Copelan
Journal:  N Engl J Med       Date:  2006-04-27       Impact factor: 91.245

3.  Granzyme A initiates an alternative pathway for granule-mediated apoptosis.

Authors:  S Shresta; T A Graubert; D A Thomas; S Z Raptis; T J Ley
Journal:  Immunity       Date:  1999-05       Impact factor: 31.745

4.  Combination of intra-bone marrow-bone marrow transplantation and subcutaneous donor splenocyte injection diminishes risk of graft-versus-host disease and enhances survival rate.

Authors:  Ming Shi; Yasushi Adachi; Yunze Cui; Ming Li; Zhexiong Lian; Yuming Zhang; Seiji Yanai; Chieko Shima; Yuichiro Imai; Susumu Ikehara
Journal:  Stem Cells Dev       Date:  2010-12-22       Impact factor: 3.272

5.  The cathepsin B death pathway contributes to TNF plus IFN-gamma-mediated human endothelial injury.

Authors:  Jie Hui Li; Jordan S Pober
Journal:  J Immunol       Date:  2005-08-01       Impact factor: 5.422

6.  Granzyme B and the downstream granzymes C and/or F are important for cytotoxic lymphocyte functions.

Authors:  Paula A Revell; William J Grossman; Dori A Thomas; Xuefang Cao; Rajesh Behl; Jane A Ratner; Zhi Hong Lu; Timothy J Ley
Journal:  J Immunol       Date:  2005-02-15       Impact factor: 5.422

7.  Serine protease inhibitor 6 protects cytotoxic T cells from self-inflicted injury by ensuring the integrity of cytotoxic granules.

Authors:  Manling Zhang; Sun-Mi Park; Yue Wang; Ramila Shah; Ni Liu; Andrea E Murmann; Chyung-Ru Wang; Marcus E Peter; Philip G Ashton-Rickardt
Journal:  Immunity       Date:  2006-04       Impact factor: 31.745

8.  Granzyme B is not required for regulatory T cell-mediated suppression of graft-versus-host disease.

Authors:  Sheng F Cai; Xuefang Cao; Anjum Hassan; Todd A Fehniger; Timothy J Ley
Journal:  Blood       Date:  2009-11-13       Impact factor: 22.113

9.  Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease.

Authors:  Alan M Hanash; Jarrod A Dudakov; Guoqiang Hua; Margaret H O'Connor; Lauren F Young; Natalie V Singer; Mallory L West; Robert R Jenq; Amanda M Holland; Lucy W Kappel; Arnab Ghosh; Jennifer J Tsai; Uttam K Rao; Nury L Yim; Odette M Smith; Enrico Velardi; Elena B Hawryluk; George F Murphy; Chen Liu; Lynette A Fouser; Richard Kolesnick; Bruce R Blazar; Marcel R M van den Brink
Journal:  Immunity       Date:  2012-08-24       Impact factor: 31.745

10.  The role of granzyme B in murine models of acute graft-versus-host disease and graft rejection.

Authors:  T A Graubert; J H Russell; T J Ley
Journal:  Blood       Date:  1996-02-15       Impact factor: 22.113

View more
  11 in total

1.  Blockade of Host β2-Adrenergic Receptor Enhances Graft-versus-Tumor Effect through Modulating APCs.

Authors:  Hemn Mohammadpour; Rachel O'Neil; Jingxin Qiu; Philip L McCarthy; Elizabeth A Repasky; Xuefang Cao
Journal:  J Immunol       Date:  2018-02-14       Impact factor: 5.422

2.  T Cell-Derived CD70 Delivers an Immune Checkpoint Function in Inflammatory T Cell Responses.

Authors:  Rachel E O'Neill; Wei Du; Hemn Mohammadpour; Emad Alqassim; Jingxin Qiu; George Chen; Philip L McCarthy; Kelvin P Lee; Xuefang Cao
Journal:  J Immunol       Date:  2017-10-18       Impact factor: 5.422

3.  Host-Derived CD70 Suppresses Murine Graft-versus-Host Disease by Limiting Donor T Cell Expansion and Effector Function.

Authors:  Nicholas D Leigh; Rachel E O'Neill; Wei Du; Chuan Chen; Jingxin Qiu; Jonathan D Ashwell; Philip L McCarthy; George L Chen; Xuefang Cao
Journal:  J Immunol       Date:  2017-05-26       Impact factor: 5.422

4.  Serine protease inhibitor 6 protects alloreactive T cells from Granzyme B-mediated mitochondrial damage without affecting graft-versus-tumor effect.

Authors:  Wei Du; Hemn Mohammadpour; Rachel E O'Neill; Sandeep Kumar; Chuan Chen; Michelle Qiu; Lin Mei; Jingxin Qiu; Philip L McCarthy; Kelvin P Lee; Xuefang Cao
Journal:  Oncoimmunology       Date:  2017-11-16       Impact factor: 8.110

5.  Host-Derived Serine Protease Inhibitor 6 Provides Granzyme B-Independent Protection of Intestinal Epithelial Cells in Murine Graft-versus-Host Disease.

Authors:  Hemn Mohammadpour; Wei Du; Rachel O'Neill; Saeed Khalili; Jingxin Qiu; Elizabeth A Repasky; Philip L McCarthy; Xuefang Cao
Journal:  Biol Blood Marrow Transplant       Date:  2018-07-10       Impact factor: 5.742

6.  MyD88 Costimulation in Donor CD8+ T Cells Enhances the Graft-versus-Tumor Effect in Murine Hematopoietic Cell Transplantation.

Authors:  Nicholas G Ciavattone; Long Wu; Rachel O'Neill; Jingxin Qiu; Eduardo Davila; Xuefang Cao
Journal:  J Immunol       Date:  2021-01-06       Impact factor: 5.422

7.  Targeting Cytokines in GVHD Therapy.

Authors:  Sandeep Kumar; Hemn Mohammadpour; Xuefang Cao
Journal:  J Immunol Res Ther       Date:  2017-06-28

8.  Somatic mTOR mutation in clonally expanded T lymphocytes associated with chronic graft versus host disease.

Authors:  Daehong Kim; Giljun Park; Jani Huuhtanen; Sofie Lundgren; Rajiv K Khajuria; Ana M Hurtado; Cecilia Muñoz-Calleja; Laura Cardeñoso; Valle Gómez-García de Soria; Tzu Hua Chen-Liang; Samuli Eldfors; Pekka Ellonen; Sari Hannula; Matti Kankainen; Oscar Bruck; Anna Kreutzman; Urpu Salmenniemi; Tapio Lönnberg; Andrés Jerez; Maija Itälä-Remes; Mikko Myllymäki; Mikko A I Keränen; Satu Mustjoki
Journal:  Nat Commun       Date:  2020-05-07       Impact factor: 14.919

Review 9.  Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation.

Authors:  Wei Du; Xuefang Cao
Journal:  Front Immunol       Date:  2018-12-19       Impact factor: 7.561

10.  Granzyme B prevents aberrant IL-17 production and intestinal pathogenicity in CD4+ T cells.

Authors:  Michael J Greer; Kathleen G McClanahan; Kristen L Hoek; Ali Nazmi; M Blanca Piazuelo; Kshipra Singh; Keith T Wilson; Danyvid Olivares-Villagómez
Journal:  Mucosal Immunol       Date:  2021-06-28       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.